Edition:
United Kingdom

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

48.86USD
16 Feb 2018
Change (% chg)

$-0.28 (-0.57%)
Prev Close
$49.14
Open
$48.99
Day's High
$49.33
Day's Low
$48.27
Volume
442,220
Avg. Vol
673,199
52-wk High
$63.60
52-wk Low
$19.54

Latest Key Developments (Source: Significant Developments)

Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025.  Full Article

Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION.  Full Article

Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING.EXACT SCIENCES - ON DEC. 15, UNIT ENTERED LOAN AGREEMENT FOR A NON-REVOLVING CONSTRUCTION LOAN OF UP TO $25.6 MILLION.  Full Article

Exact Sciences reports qtrly loss per share of $0.23
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Exact Sciences Corp ::Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent.Exact Sciences Corp sees 2017 revenue of $254 million to $257 million.  Full Article

David Shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing
Thursday, 25 Aug 2016 

Exact Sciences Corp :David shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing.  Full Article

Exact Sciences files for potential mixed shelf - SEC filing
Wednesday, 27 Jul 2016 

Exact Sciences Corp :Files for potential mixed shelf - SEC filing.  Full Article

Exact Sciences posts Q2 loss per share of $0.46
Tuesday, 26 Jul 2016 

Exact Sciences Corp : Generated revenues of $21.2 million during Q2 ended June 30, 2016, representing a 161-percent increase from $8.1 million in Q2 of 2015 . Q2 loss per share $0.46 . Continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating revenue of $90 to $100 million for 2016 . Q2 earnings per share view $-0.55, revenue view $18.5 million -- Thomson Reuters I/B/E/S .FY2016 revenue view $86.6 million -- Thomson Reuters I/B/E/S.  Full Article

Exact Sciences'Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations
Wednesday, 15 Jun 2016 

: Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations .Exact Sciences Corp says final recommendations also recognize use of cologuard every three years.  Full Article

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025